Related Experiment Video

Updated: Aug 20, 2026

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy?

P Verdecchia1, F Angeli, R Gattobigio

  • 1Department of Cardiovascular Disease, Hospital R. Silvestrini, Perugia, Italy. verdec@tin.it

Journal of Human Hypertension
|December 14, 2004
PubMed

Insights

Systolic blood pressure (SBP) is the primary driver of left ventricular hypertrophy (LVH) regression in hypertension. Lowering SBP effectively reduces LVH, independent of diastolic blood pressure or pulse pressure changes.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Medicine

Background:

  • Left ventricular hypertrophy (LVH) is a significant complication of hypertension.
  • Systolic blood pressure (SBP) influences LVH development and regression.
  • Comparative data on BP components' impact on LVH regression are limited.

Purpose of the Study:

  • To assess the comparative impact of different blood pressure (BP) components on left ventricular mass (LVM) regression in hypertensive patients.
  • To identify the independent determinant of LVH regression.

Main Methods:

  • Prospective study of 743 hypertensive subjects (Progetto Ipertensione Umbria Monitoraggio Ambulatoriale - PIUMA).
  • Echocardiography and 24-h ambulatory BP monitoring before and after treatment (average 3.9 years).
  • Multivariate linear regression analysis to determine independent predictors of LVM changes.

Main Results:

  • Changes in 24-h SBP, diastolic blood pressure (DBP), and pulse pressure (PP) were associated with LVM changes (r=0.40, 0.33, 0.35 respectively).
  • Clinic BP changes showed weaker associations with LVM changes.
  • 24-h SBP changes were the sole independent determinant of LVM changes (percentage changes in LVM = 0.73 x percentage changes in 24-h SBP - 0.48, P<0.0001).

Conclusions:

  • Systolic blood pressure is the principal determinant of left ventricular hypertrophy regression in hypertensive humans.
  • LVH reduction is primarily driven by SBP reduction, irrespective of DBP or PP changes.
  • Ambulatory SBP monitoring is crucial for assessing LVH regression predictors.

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...